Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Director operating in the Therapeutics space. If you think a Director is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Richard Ross
Founding Director & CSO of Diurnal Group
Richard Ross is a founding Director of Diurnal and Chief Scientific Officer and is contracted to perform work for the Group by the University pursuant to the terms of a secondment agreement and a research agreement. He is a Professor of Clinical Endocrinology and Head of the Academic Unit of Diabetes, Endocrinology and Metabolism at the University of Sheffield and was previously a Senior Lecturer at St. Bartholomew’s Hospital, London. Richard’s primary research interest is pituitary and adrenal disease with a particular focus on hormone replacement. His research has yielded over 200 papers, more than 30 granted patents and publications in Nature Medicine, Nature Reviews Endocrinology, Nature Genetics, The Lancet, The BMJ and PNAS. He has been a member of the editorial boards of Clinical Endocrinology and the Journal of Clinical Endocrinology and Metabolism and served as an elected member of the executive committees for the European Society of Endocrinology (Treasurer), the Society for Endocrinology and Growth Hormone Research Society.
Follow Richard Ross:
About Diurnal Group, University of Sheffield: Diurnal Group is an innovative pharmaceutical company creating high-value therapeutic drugs for use in the endocrine hormone area.
_______
Simon Bennett
Director, International Regulatory Affairs of Biogen Idec
Follow Simon Bennett:
About Biogen Idec: Biogen Idec is an American biotechnology company that provides therapeutics for neurological, autoimmune, and rare diseases.
Hendrik-Tobias Arkenau
Executive Medical Director of Sarah Cannon
Professor Tobias Arkenau joined Sarah Cannon Research Institute as Executive Medical Director in 2010.
Follow Hendrik-Tobias Arkenau:
About HCA International, Sarah Cannon, UCL: Sarah Cannon offers integrated cancer services with convenient access to cutting-edge therapies.
Chris Jones
Non Executive Director & Special Advisor of MediSieve
Chris Jones joined Elasmogen as Executive Chairman in 2016.
Follow Chris Jones:
About Elasmogen, MediSieve, Mologic: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Himanshu Kataria
Founder, CEO and Managing Director of CLYZ Labs
Himanshu is an experienced NHS Academic Clinician with emergency medicine background (>10 years clinical experience). Himanshu has substantial experience in setup and delivery of clinical research trials, as a specialty lead within Clinical Research Network for the whole of North West Coast of England delivering research in >23 NHS Partner organisations. Himanshu is an MBBS, MBBS, MRCSed (A&E), MRCEM, FRCEM, ALS Instructor. With a number of years in both clinical and research experience, Himanshu has held various consultancy posts in notable hospitals/medical facilities such as Whiston Hospital in Merseyside. He also held the Special Group Lead position within the Clinical Research Network – North West Coast: Research Delivery arm of the NIHR (National Institute of Health Research). In addition to his qualifications as a Medical Doctor, Himanshu has held a number of entrepreneurial roles over the past few years in bio-medical companies such as Indu Stem Cell Technology Plc, and Transgenex Inc in the USA. Dr Kataria is familiar with financial management of the business owing to his experience in Clinical Finance Limited which advised for fundraising for Indu Stem Cell Technology PLC. He continues to serve as a director for Indu Stem Cell Technology PLC.
Follow Himanshu Kataria:
About CLYZ Labs: CLYZ Labs are developing a testing service to select the best drug therapy for personalised cancer treatment.
Adam George
UK Managing Director of GW Pharmaceuticals
Adam George has served as our Managing Director – UK since March 2017. Mr. George also acts as our Company Secretary. Prior to taking on his current role, Mr. George served as our Chief Financial Officer since 2012 and Financial Controller since 2007. Mr. George has previously occupied several senior finance roles within both public and privately-owned companies, most recently as Finance Director from 2004 to 2007 and as Group Financial Controller from 2001 to 2004 of Believe It Group Limited (now 4Com plc), a telecommunications service provider. Mr. George holds an BSc. in Biology from Bristol University and is qualified as a chartered accountant.
Follow Adam George:
About GW Pharmaceuticals: GW Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics.
Gil McVean
Co Founder & Director of Genomics
Gil McVean is Professor of Statistical Genetics at the University of Oxford and Head of Bioinformatics and Statistical Genetics at the Wellcome Trust Centre for Human Genetics. After an undergraduate training in Zoology, he obtained a PhD with Laurence Hurst in Cambridge and worked with Brian and Deborah Charlesworth in Edinburgh before joining Oxford in 2000. His research focuses on understanding the molecular and evolutionary processes that shape genetic variation in populations and the relationship between genetic variation and phenotype. He has made contributions to our understanding of areas including recombination hotspots, historical patterns of natural selection, the male mutation rate, human genetic variation, the role of HLA in complex disease and genealogical processes. He has played a leading role in the HapMap and 1000 Genomes Projects and currently works on organisms from HIV to malaria.
Follow Gil McVean:
About Genomics: Genomics plc aiming to lead the genomic transformation of healthcare.
Jonathan Hollick
Managing Director of Breakpoint Therapeutics
Follow Jonathan Hollick:
About Breakpoint Therapeutics: Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs.
Roy Lobb
Director and Co-founder of Aleta Biotherapeutics
Roy Lobb is the Director and Co-founder at Aleta Biotherapeutics.
Follow Roy Lobb:
About Advent Life Sciences, Aleta Biotherapeutics: Aleta Biotherapeutics focuses on transforming cellular therapeutics to allow a broader spectrum of cancer indications to be targeted.
Ian Abercrombie
Business Unit Director & Chief Operating Officer of NuCana BioMed
Ian Abercrombie has over 25 years experience in the biopharmaceutical and healthcare industry. Ian’s specific expertise includes the clinical development and commercialisation of anti-cancer medicines and companion diagnostics to enable therapies to be targeted to specific patient populations. Ian has wide biopharmaceutical and healthcare experience having initially served in the public health sector before working for Janssen Cilag, Ortho-Biotech, Bioenvision and Caris Life Sciences. Whilst at Bioenvision, Ian played a major role in developing and commercialising clofarabine, the first new drug to be approved specifically for childhood acute leukaemia in Europe for over thirty years.
Follow Ian Abercrombie:
About Medannex Ltd, NuCana BioMed: NuCana BioMed, a biopharmaceutical company, develops and commercializes rationally designed medicines for significant unmet medical needs.
Liam Mcquillan
Director of Liopa
Follow Liam Mcquillan:
About Catalyst, Liopa: Liopa’s LipRead deciphers speech from lip movements. It uses AI and deep learning for automated lip reading.
Miles Houslay
Chief Scientific Officer and Director of Mironid
Follow Miles Houslay:
About King’s College London, Mironid, University of Glasgow: Mironid is a drug discovery company focused on therapeutics for degenerative kidney diseases, chronic inflammatory diseases, and cancer.
Benedikt Reinke
Co-Founder & Managing Director of Sympatient
Benedikt Reinke is the Co-Founder & Managing Director at Sympatient GmbH
Follow Benedikt Reinke:
About Sympatient: Sympatient is building the first digital anxiety clinic.
David Jones
CSA, Co-Founder, Director of Re-Vana Therapeutics
David Jones is the Elected Fellow at Royal Statistical Society.
Follow David Jones:
About Irish Academy of Engineering, Queen’s University Belfast, Re-Vana Therapeutics, Royal Academy of Engineering, Royal Statistical Society, The Institute of Materials, Minerals and Mining, The Royal Society of Chemistry: Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company.
Douglas Higgins
Founder & Director of Mujo Mechanics
Douglas Higgins is the Founder & Director at Mujo Mechanics.
Follow Douglas Higgins:
About Mujo Mechanics: Mujo Mechanics provides smart devices and intelligent cloud platform for a data-driven approach to musculoskeletal health.
Geri McMahon
Non-Executive Director of Mujo Mechanics
Geri McMahon Managing Director joined MUJO following eight years in investment banking to coordinate and drive the team to deliver the MUJO vision. Geri brings a focus on operational excellence, and a wealth of international business experience having worked with government institutions and corporates across EMEA, APAC and AMERICAS regions. Geri holds a combined Finance and Commerce degree with Chinese language from the University of Sydney and previously worked on the trading floors of both RBS and Bank of America Merrill Lynch in Sydney and London.
Follow Geri McMahon:
About Mujo Mechanics: Mujo Mechanics provides smart devices and intelligent cloud platform for a data-driven approach to musculoskeletal health.
Sheraz Daya
Founder, Chairman & Medical Director of Centre for Sight
Follow Sheraz Daya:
About Centre for Sight: Centre for Sight provides eye care services, from basic diagnostic and therapeutic services to complex operative procedures.
